ERBB2 and breast carcinoma: Ongoing trials looking at the role of T-DXd in HER2-positive disease include DESTINY05, which compares T-DXd and T-DM1 for patients with early breast cancer who have residual disease post neoadjuvant chemotherapy [14], DESTINY07 and 09 looking at T-DXd in combination with other agents for first-line therapy of metastatic breast cancer [15,16], and DESTINY11 will examine the role of neoadjuvant T-DXd versus standard of care chemotherapy and dual-targeted anti-HER2 therapy for high-risk early breast cancer (T3/4 and/or node-positive) [17].